Diseases / Bacterial Infections
Bacterial Infections
DiseaseBacterial infections are illnesses caused by pathogenic bacteria invading tissues or organs. They range from mild localized infections to severe systemic disease and are typically treated with appropriate antibiotics when indicated.
- Trials
- 583
- Recruiting
- 45
- Completed
- 382
- With results
- 99
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 1 | 1 | — | — | 2 | — | 5 |
| Phase 1 | 4 | 2 | — | — | 93 | 7 | 5 | — | 6 | — | 117 |
| Phase 1/2 | — | — | — | — | 6 | 2 | 2 | — | 2 | — | 12 |
| Phase 2 | 2 | 1 | — | 1 | 31 | 2 | 3 | — | 2 | — | 42 |
| Phase 2/3 | 1 | — | — | 1 | 2 | — | — | — | — | — | 4 |
| Phase 3 | 2 | — | — | 1 | 53 | 6 | — | — | 3 | — | 65 |
| Phase 4 | 5 | 1 | — | 1 | 34 | 3 | — | — | 3 | — | 47 |
| Not applicable | 11 | 2 | — | 1 | 62 | 4 | 2 | — | 22 | — | 104 |
| Unknown | 19 | 13 | 3 | 1 | 100 | 9 | 1 | 1 | 39 | 1 | 187 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Bacterial Infections | 5 | 117 | 12 | 42 | 4 | 65 | 47 | 104 | 187 | 583 |
| Infections | — | 4 | 1 | 5 | 2 | 8 | 9 | 12 | 19 | 60 |
| Virus Diseases | — | — | — | 3 | — | 7 | — | 8 | 25 | 43 |
| Sepsis | — | — | 1 | — | 1 | 3 | 4 | 5 | 26 | 40 |
| Pneumonia | — | — | — | 8 | 2 | 2 | 2 | — | 10 | 24 |
| Gram-Positive Bacterial Infections | — | 2 | — | 5 | 1 | 6 | — | — | 6 | 20 |
| Mycoses | — | 2 | 1 | 1 | — | 2 | — | 4 | 10 | 20 |
| Urinary Tract Infections | 1 | 2 | — | 1 | — | 4 | 3 | 2 | 7 | 20 |
| Communicable Diseases | — | 2 | 1 | 3 | — | 5 | — | 5 | 3 | 19 |
| Respiratory Tract Infections | 1 | 3 | — | 4 | — | 1 | 2 | 3 | 5 | 19 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | GlaxoSmithKline | 35 | 0 |
| 2 | National Institute of Allergy and Infectious Diseases (NIAID) | 17 | 4 |
| 3 | Wyeth is now a wholly owned subsidiary of Pfizer | 15 | 5 |
| 4 | Pfizer | 13 | 4 |
| 5 | Qpex Biopharma, Inc. | 9 | 0 |
| 6 | Merck Sharp & Dohme LLC | 8 | 3 |
| 7 | Assistance Publique - Hôpitaux de Paris | 6 | 0 |
| 8 | Radboud University Medical Center | 6 | 0 |
| 9 | Emergent BioSolutions | 5 | 0 |
| 10 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 5 | 3 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Linezolid | 14 |
| 2 | Vancomycin | 13 |
| 3 | Azithromycin | 12 |
| 4 | gepotidacin | 11 |
| 5 | Meropenem | 11 |
| 6 | Moxifloxacin | 10 |
| 7 | Aztreonam | 9 |
| 8 | Clindamycin | 9 |
| 9 | 13-valent pneumococcal vaccine | 8 |
| 10 | GSK1322322 | 8 |
Evidence
- Results reported
- 25.9%99 of 382 completed
- Published
- 10.5%40 of 382 completed
- Primary endpoint met
- 92.2%71 of 77 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 107
- Median duration
- 19months
- Countries
- 86
- Study sites
- 2882
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 30
- Phase 1
- 39
- Phase 1/2
- 56
- Phase 2
- 135
- Phase 2/3
- 506
- Phase 3
- 426
- Phase 4
- 150
- Not applicable
- 120
- Unknown
- 196
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 25 |
| 2 | New York | United States | 25 |
| 3 | Los Angeles | United States | 24 |
| 4 | Baltimore | United States | 23 |
| 5 | Chicago | United States | 23 |
| 6 | Boston | United States | 20 |
| 7 | Detroit | United States | 20 |
| 8 | Philadelphia | United States | 20 |
| 9 | Columbus | United States | 19 |
| 10 | Pittsburgh | United States | 19 |
Terminations
- Terminated
- 34
- Withdrawn
- 13
- Suspended
- 1
- Stopped for recruitment
- 1.9%11 of 583 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT05914467 Terminated | Terminated | The intervention was deemed futile the intervention group, as TDM was not needed in patients with a 12mg/kg dose. In consultation with the METC and biostatistics it was decided to terminate the study early. | 2026-02-20 |
| NCT06418711 Terminated | Terminated | Futility | 2025-11-10 |
| NCT05269121 Withdrawn | Withdrawn | Sponsor Decision | 2024-11-30 |
| NCT05340257 Withdrawn | Withdrawn | Business Decision | 2024-07-08 |
| NCT05942820 Terminated | Terminated | CMC challenges | 2024-02-15 |
| NCT02655302 Terminated | Terminated | sponsor decision (COVID) | 2023-09-13 |
| NCT04783727 Terminated | Terminated | Change in WHO recommendations for standard of care (control arm); availability of new shorter treatment regimens for MDR-TB; war in Ukraine where two study sites are located; key trial team members left the team. | 2022-11-01 |
| NCT04280354 Terminated | Terminated | Recruitment failure | 2022-07-31 |
| NCT03143920 Terminated | Terminated | No funding to continue | 2022-07-07 |
| NCT04664075 Terminated | Terminated | The study failed to recruit sufficient number of participants. | 2022-04-30 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above:
Search all Bacterial Infections trials on ClinicalTrials.gov →